Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A carries a market capitalization of 7.76B, placing it among publicly traded companies globally. Its enterprise value stands at 6.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A has 176.53M shares outstanding.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 28.43. The price-to-sales ratio is 5.81, and the price-to-book ratio stands at 2.65.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A trades at an EV/EBITDA multiple of 21.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.33B versus a market cap of 7.76B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.92, indicating elevated leverage, while an interest coverage ratio of 115.04 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A posted a return on equity (ROE) of 9.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.28 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.40, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.53, useful for judging operating efficiency across full business cycles. The company generates approximately 885,583.87 in revenue per employee across its workforce of 1,490.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.44 indicates how many times Chengdu Easton Biopharmaceuticals Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A recorded 37.63M in income tax expense. That works out to an effective tax rate of 13.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 279.13M, leaving 269.63M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A's stock has declined approximately 15.16% over the past 52 weeks. The 50-day moving average sits at 47.04, while the 200-day moving average is 55.14.

Over the twelve months ended June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A generated 1.32B in revenue and converted that into 269.63M in net income, yielding earnings per share of 1.38. EBITDA reached 292.84M, while operating income came in at 225.58M.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A holds 1.67B in cash and equivalents against 148.75M in total debt, resulting in a net debt position of -183.66M. Total book value stands at 2.93B, with working capital of 1.50B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A posted a gross margin of 74.84, reflecting its pricing power and cost economics. The operating margin of 17.09 and net profit margin of 20.43 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A paid dividends of 0.93 per share. The dividend payout ratio of 72.16 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chengdu Easton Biopharmaceuticals Co., Ltd. Class A shareholders.

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A's most recent stock split took place on July 1, 2024 with a 100:147 split ratio.

As of June 30, 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. Class A has an Altman Z-Score of 7.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.